Prognostic Significance of 18F-fluorodeoxyglucose Positron Emission Tomography (PET)-based Parameters in Neoadjuvant Chemoradiation Treatment of Esophageal Carcinoma

  • Ma, Jin-Bo (Department of Radiation Oncology, Yantai Yuhuangding Hospital, School of Medicine) ;
  • Chen, Er-Cheng (Department of Radiation Oncology, Yantai Yuhuangding Hospital, School of Medicine) ;
  • Song, Yi-Peng (Department of Radiation Oncology, Yantai Yuhuangding Hospital, School of Medicine) ;
  • Liu, Peng (Department of Radiation Oncology, Yantai Yuhuangding Hospital, School of Medicine) ;
  • Jiang, Wei (Department of Radiation Oncology, Yantai Yuhuangding Hospital, School of Medicine) ;
  • Li, Ming-Huan (Department of Radiation Oncology, Shandong Cancer Hospital & Institute) ;
  • Yu, Jin-Ming (Department of Radiation Oncology, Shandong Cancer Hospital & Institute)
  • Published : 2013.04.30


Aims and Background: The purpose of the research was to study the prognostic value of tumor 18F-FDG PET-based parameters in neoadjuvant chemoradiation for patients with squamous esophageal carcinoma. Methods: Sixty patients received chemoradiation therapy followed by esophagectomy and two 18FDG-PET examinations at pre- and post-radiation therapy. PET-based metabolic-response parameters were calculated based on histopathologic response. Linear regression correlation and Cox proportional hazards models were used to determine prognostic value of all PET-based parameters with reference to overall survival. Results: Sensitivity (88.2%) and specificity (86.5%) of a percentage decrease of SUVmax were better than other PET-based parameters for prediction of histopathologic response. Only percentage decrease of SUVmax and tumor length correlated with overall survival time (linear regression coefficient ${\beta}$: 0.704 and 0.684, P<0.05). The Cox proportional hazards model indicated higher hazard ratio (HR=0.897, P=0.002) with decrease of SUVmax compared with decrease of tumor size (HR=0.813, P=0.009). Conclusion: Decrease of SUVmax and tumor size are significant prognostic factors in chemoradiation of esophageal carcinoma.


  1. Akutsu Y, Matsubara H, Shuto K, et al (2009). Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg, 33, 1002-9.
  2. Becker K, Mueller JD, Schulmacher C, et al (2003). Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer, 98, 1521-30.
  3. Cescon DW, Hopkins JP, Bradbury PA, et al (2009). Epidemiology of Esophageal Cancer: Molecular. Esophageal cancer: principles and practice, 93.
  4. Chang F, Deere H, Mahadeva U, George S (2008). Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol, 129, 252-62.
  5. Choi NC, Fischman AJ, Niemierko A, et al (2002). Doseresponse relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 54, 1024-35.
  6. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Lippincott Williams & Wilkins 2008.
  7. Gillham CM, Lucey JA, Keogan M, et al (2006). (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer, 95, 1174-9.
  8. Heilmann HP, Molls M, Nieder C, et al. Radiation Oncology: An Evidence-based Approach. Springer 2008.
  9. Hiyoshi Y, Watanabe M, Imamura Y, et al (2009). The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. Oncology, 76, 286-92.
  10. Javeri H, Xiao L, Rohren E, et al (2009a). Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer, 115, 624-30.
  11. Javeri H, Xiao L, Rohren E, et al (2009b). The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer, 115, 5184-92.
  12. Jingu K, Kaneta T, Nemoto K, et al (2010). (18) F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. Int J Clin Oncol, 15, 184-90.
  13. Kim MK, Ryu JS, Kim SB, et al (2007). Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer, 43, 1385-91.
  14. Klaeser B, Nitzsche E, Schuller JC, et al (2009). Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie, 32, 724-30.
  15. Roedl JB, Harisinghani MG, Colen RR, et al (2008). Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg, 86, 1131-8.
  16. Schmidt M, Bollschweiler E, Dietlein M, et al (2009). Mean and maximum standardized uptake values in [18F]FDGPET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging, 36, 735-44.
  17. Suzuki A, Xiao L, Hayashi Y, et al (2011). Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer, 117, 4823-33.
  18. Tong DK, Law S, Kwong DL, et al (2010). Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol, 17, 2184-92.

Cited by

  1. Combination of FDG PET/CT and Contrast-Enhanced MSCT in Detecting Lymph Node Metastasis of Esophageal Cancer vol.15, pp.18, 2014,
  2. Standardized Uptake Values Highly Correlate with Tumor Size and Fuhrman Grade in Patients with Clear Cell Renal Cell Carcinoma vol.15, pp.18, 2014,
  3. Pre-treatment Metabolic Tumor Volume and Total Lesion Glycolysis are Useful Prognostic Factors for Esophageal Squamous Cell Cancer Patients vol.15, pp.3, 2014,
  4. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer vol.39, pp.3, 2016,
  5. F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis pp.1465-3621, 2016,